Association Between Lymphopenia and Survival Outcomes in Esophageal Carcinoma Patients Receiving Combined Immunotherapy and Chemoradiotherapy.

Xingyuan ChengBaoqing ChenSifen WangJun ZhangJinhan ZhuMengzhong LiuShiliang LiuMian Xi

Published in: The oncologist (2023)

The addition of anti-PD-1 immunotherapy to definitive CRT could mitigate the decline of ALC during radiotherapy and might prolong survival. Low ALC nadir was correlated to worse PFS, larger PTV, and higher heart V5 in patients receiving combined immunotherapy and CRT.

Keyphrases

locally advanced
rectal cancer
cardiac resynchronization therapy
early stage
heart failure
radiation therapy
squamous cell carcinoma